Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals (REGN) and Sanofi have received a positive opinion from the European Medicines Agency's CHMP for Dupixent (dupilumab) to treat moderate-to-severe chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and older who have an inadequate response to H1 antihistamines and are naive to anti-IgE therapy. This recommendation positions Dupixent for potential EU approval, expanding its market reach beyond existing approvals in the U.S. and Japan, and signifies a significant step in addressing an unmet medical need in this patient population.

Analysis

Regeneron Pharmaceuticals (REGN) and its partner Sanofi have secured a significant regulatory milestone with a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for their drug Dupixent. This recommendation is for an expanded indication to treat moderate-to-severe chronic spontaneous urticaria (CSU) in adults and adolescents who have not responded adequately to H1 antihistamines. The CHMP's endorsement is a strong precursor to final EU approval, which is anticipated in the coming months. This development is material as it would open a new European market for Dupixent in this specific indication, building on its existing approvals for CSU in the United States and Japan. The positive opinion reinforces the drug's clinical profile and positions both companies to capitalize on an unmet medical need within a defined patient population, thereby potentially enhancing future revenue streams from this key pharmaceutical asset.

Key Decisions for Investors

• The positive CHMP opinion materially de-risks the EU approval for Dupixent's new indication, strengthening the fundamental growth outlook for both Regeneron and Sanofi.
• Investors should monitor for the final European Commission decision in the coming months, as formal approval will be the primary catalyst for upward revisions to revenue models for this key asset.
• Consider this regulatory milestone as a validation of the companies' pipeline execution, potentially justifying a decision to hold or add to existing positions in REGN and SNY pending the final approval.